Monitoring the biological effect of BMP-2 release on bone healing by PET/CT.
Bone morphogenetic protein-2 (BMP-2) releasing scaffolds are routinely used in bone tissue engineering to accelerate regeneration. Thus, assessing growth factor activity, and tissue regeneration around a biomaterial delivery system is extremely important to optimize the stages of bone healing. Such assessment commonly relies on histology. A non-invasive method would allow longitudinal monitoring of the regeneration process. The present study sought to explore the feasibility of Positron Emission Tomography (PET) as a non-invasive method to monitor the osteogenic potential of a BMP-2 releasing calcium phosphate cement (CPC) bone substitute. In a calvarial defect model in rats, (18)F-Fluoride PET was used to quantify (18)F-Fluoride uptake around the BMP-2/CPC material. As controls, non-loaded porous CPC, dense CPC and autograft samples were used. PET was performed every two weeks, during a period of 8weeks post-implantation. In parallel, computed tomography (CT) imaging was performed for anatomical reference. Four specimens were evaluated per group per time point. The highest (18)F-Fluoride signal intensity was measured in the BMP-2 group (approximately 5 times higher than the baseline value), followed by the controls in the order, from high to low, porous, dense and autograft. The same trend was maintained during the entire experimental period. Histology and measurements of the bone volume percentage confirmed the significantly higher new bone formation in the BMP-2 releasing group (about 25%), compared to the controls. Moreover, (18)F-Fluoride PET uptake showed a statistically significant positive correlation (r=0.6038, P=0.0171) with the newly formed bone volume. In conclusion, our results support the use of a PET/CT method for the longitudinal monitoring of BMP-2 releasing scaffolds, in vivo.
Departments of Biomaterials, Radboudumc, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Manuela
M
Ventura
Departments of Nuclear Medicine, Radboudumc, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Otto C
OC
Boerman
Departments of Nuclear Medicine, Radboudumc, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Gerben M
GM
Franssen
Departments of Biomaterials, Radboudumc, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Ewald
E
Bronkhorst
Departments of Biomaterials, Radboudumc, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: John.Jansen@radboudumc.nl.
John A
JA
Jansen
Departments of Biomaterials, Radboudumc, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
X Frank
XF
Walboomers
D000818:Animals; D001843:Bone Cements; D055396:Bone Morphogenetic Protein 2 / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D001861:Bone Regeneration / Q000187:drug effects; D002130:Calcium Phosphates / Q000737:chemistry; D006259:Craniocerebral Trauma / Q000188:drug therapy / Q000503:physiopathology; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000737:chemistry; D004339:Drug Compounding; D065546:Drug Liberation; D016903:Drug Monitoring / Q000295:instrumentation / Q000379:methods*; D019788:Fluorodeoxyglucose F18; D008297:Male; D049268:Positron-Emission Tomography; D017208:Rats, Wistar; D012886:Skull / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000293:injuries; D023822:Tissue Engineering
C525719:Bmp2 protein, mouse; D001843:Bone Cements; D055396:Bone Morphogenetic Protein 2; D002130:Calcium Phosphates; D004337:Drug Carriers; D019788:Fluorodeoxyglucose F18; C020243:calcium phosphate
BMP (bone morphogenetic protein); Bone tissue engineering; Calcium phosphate cement; Drug delivery; Positron Emission Tomography; Small animal imaging